Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation

Verified

Overview

The purpose of this study is to see if a condensed version of the chemotherapy regimen busulfan, melphalan, fludarabine (bu/mel/flu) and the drug antithymocyte globulin (ATG-also referred to as rATG or thymoglobulin) can have the same or fewer number of severe side effects in people with various blood cancers 30 days after they receive an allogeneic hematopoietic cell transplantation.

SparkCures ID 1135
Trial Phase Phase 1
Enrollment 45 Patients
Treatments
Trial Sponsors
  • Memorial Sloan Kettering Cancer Center
NCT Identifier

NCT04098393

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

Inclusion Criteria:

  • Patients aged ≥ 18 years old.
  • Patients with any of the following hematologic malignancies for which allo-HCT is indicated, including:
    • Acute myeloid leukemia (AML) with intermediate or high-risk features in CR1.
    • Relapsed AML in ≥ CR2.
    • Acute leukemias of ambiguous lineage in ≥ CR1.
    • Acute lymphoid leukemia (ALL) in CR1 with clinical, flow cytometric, or molecular features indicating a high risk for relapse, or ALL in ≥ CR2.
    • CML meeting one of the following criteria:
    • Failed response to or intolerant to BCR-ABL tyrosine kinase inhibitors (TKIs).
    • CML with BCR-ABL mutation consistent with poor response to TKIs (e.g., T315I mutation)
    • CML in accelerated phase or blast crisis with <10% blasts after therapy, or in second chronic phase.
    • Myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), or MDS/MPN overlap syndromes with least one of the following:
    • Revised International Prognostic Scoring System risk score of intermediate or higher at the time of transplant evaluation.
    • Life-threatening cytopenias.
    • Karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53, or complex or monosomal karyotype.
    • Therapy related disease or disease evolving from other malignant processes.
    • Chronic myelomonocytic leukemia (CMML-1 or CMML-2).
    • Severe aplastic anemia.
    • Relapsed Hodgkin lymphoma meeting both of the following criteria:
    • Responding to therapy prior to enrollment.
    • Relapse after autologous HCT or are ineligible for autologous HCT.
    • Relapsed non-Hodgkin lymphoma meeting both of the following criteria:
    • Responding to therapy prior to enrollment.
    • Relapse after prior autologous HCT or are ineligible for autologous HCT.
    • High-risk multiple myeloma following autologous HCT or relapsed multiple myeloma following autologous HCT with chemosensitive disease.
  • Adequate organ function is required, defined as follows:
    • Serum bilirubin ≤ 2 mg/dL, unless benign congenital hyperbilirubinemia. Patients with hyperbilirubinemia related to paroxysmal nocturnal hemoglobinuria or other hemolytic disorders are eligible with PI approval.
    • AST, ALT, and alkaline phosphatase < 3 times the upper limit of normal unless thought to be disease-related.
    • Creatinine clearance ≥ 50 ml/min (calculated by Cockcroft Gault)
    • LVEF ≥ 45% by MUGA or resting echocardiogram.
    • Pulmonary function (FEV1 and corrected DLCO) ≥ 50% predicted.
  • Adequate performance status of ECOG ≤ 2.
  • Each patient must be willing to participate as a research subject and must sign an informed consent form.

Exclusion Criteria:

  • Patients with active extramedullary disease.
  • Patients with active central nervous system malignancy.
  • Active and/or uncontrolled infection at the time of allo-HCT.
  • Patients who have undergone previous allo-HCT.
  • Patients who have undergone previous autologous HCT within the last 6 months, with the exclusion of high-risk multiple myeloma patients.
  • Patient seropositivity for HIV I/II and/or HTLV I/II.
  • Females who are pregnant or breastfeeding.
  • Patients unwilling to use contraception during the study period.
  • Patient or guardian unable to give informed consent or unable to comply with the treatment protocol.

Donor Inclusion and Exclusion Criteria:

 

  • Must be a 10/10 HLA genotypically matched related or unrelated donor at A, B, C, DRB1, and DQB1 loci, as tested by DNA analysis.
  • Able to provide informed consent for the donation process per institutional standards.
  • Meet standard criteria for donor collection as defined by the National Marrow Donor Program Guidelines.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Patients aged ≥ 18 years old.
  • Patients with any of the following hematologic malignancies for which allo-HCT is indicated, including:
    • Acute myeloid leukemia (AML) with intermediate or high-risk features in CR1.
    • Relapsed AML in ≥ CR2.
    • Acute leukemias of ambiguous lineage in ≥ CR1.
    • Acute lymphoid leukemia (ALL) in CR1 with clinical, flow cytometric, or molecular features indicating a high risk for relapse, or ALL in ≥ CR2.
    • CML meeting one of the following criteria:
    • Failed response to or intolerant to BCR-ABL tyrosine kinase inhibitors (TKIs).
    • CML with BCR-ABL mutation consistent with poor response to TKIs (e.g., T315I mutation)
    • CML in accelerated phase or blast crisis with <10% blasts after therapy, or in second chronic phase.
    • Myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), or MDS/MPN overlap syndromes with least one of the following:
    • Revised International Prognostic Scoring System risk score of intermediate or higher at the time of transplant evaluation.
    • Life-threatening cytopenias.
    • Karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53, or complex or monosomal karyotype.
    • Therapy related disease or disease evolving from other malignant processes.
    • Chronic myelomonocytic leukemia (CMML-1 or CMML-2).
    • Severe aplastic anemia.
    • Relapsed Hodgkin lymphoma meeting both of the following criteria:
    • Responding to therapy prior to enrollment.
    • Relapse after autologous HCT or are ineligible for autologous HCT.
    • Relapsed non-Hodgkin lymphoma meeting both of the following criteria:
    • Responding to therapy prior to enrollment.
    • Relapse after prior autologous HCT or are ineligible for autologous HCT.
    • High-risk multiple myeloma following autologous HCT or relapsed multiple myeloma following autologous HCT with chemosensitive disease.
  • Adequate organ function is required, defined as follows:
    • Serum bilirubin ≤ 2 mg/dL, unless benign congenital hyperbilirubinemia. Patients with hyperbilirubinemia related to paroxysmal nocturnal hemoglobinuria or other hemolytic disorders are eligible with PI approval.
    • AST, ALT, and alkaline phosphatase < 3 times the upper limit of normal unless thought to be disease-related.
    • Creatinine clearance ≥ 50 ml/min (calculated by Cockcroft Gault)
    • LVEF ≥ 45% by MUGA or resting echocardiogram.
    • Pulmonary function (FEV1 and corrected DLCO) ≥ 50% predicted.
  • Adequate performance status of ECOG ≤ 2.
  • Each patient must be willing to participate as a research subject and must sign an informed consent form.

Exclusion Criteria:

  • Patients with active extramedullary disease.
  • Patients with active central nervous system malignancy.
  • Active and/or uncontrolled infection at the time of allo-HCT.
  • Patients who have undergone previous allo-HCT.
  • Patients who have undergone previous autologous HCT within the last 6 months, with the exclusion of high-risk multiple myeloma patients.
  • Patient seropositivity for HIV I/II and/or HTLV I/II.
  • Females who are pregnant or breastfeeding.
  • Patients unwilling to use contraception during the study period.
  • Patient or guardian unable to give informed consent or unable to comply with the treatment protocol.

Donor Inclusion and Exclusion Criteria:

 

  • Must be a 10/10 HLA genotypically matched related or unrelated donor at A, B, C, DRB1, and DQB1 loci, as tested by DNA analysis.
  • Able to provide informed consent for the donation process per institutional standards.
  • Meet standard criteria for donor collection as defined by the National Marrow Donor Program Guidelines.

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.

Memorial Sloan Kettering Cancer Center
New York
Memorial Sloan Kettering Cancer Center

Resources

There are no resources, links or videos to display for this clinical trial.

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Memorial Sloan Kettering Cancer Center to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors